SOHO 2026: Imetelstat Efficacy in Myelofibrosis - GERN
The updated analysis reveals promising overall survival rates for imetelstat.
Bizonyítékszint: Korai humán adat. Kis vagy feltáró emberi adat.
Kapcsolódó jelek
- ASH 2024: New Research, Data Drive Progress in Myelofibrosis
- Primary Myelofibrosis
- Extended Access of Momelotinib in Adults With Myelofibrosis
- Appraising the Use of JAK Inhibitors in Treating Myelofibrosis
- The Ongoing Challenges of Managing Cytopenic Myelofibrosis in 2025: The Emergence of Non‑JAK Inhibitor Therapies